Niagen Bioscience (NAGE) Receivables (2011 - 2026)

Niagen Bioscience (NAGE) has reported Receivables for 16 consecutive years, with $16.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 226.13% year-over-year to $16.5 million; the TTM figure through Mar 2026 stood at $16.5 million (up 226.13% YoY), while the FY2025 annual figure was $10.5 million, up 16.03% from the prior year.
• Receivables rose to $16.5 million in Q1 2026 per NAGE's latest filing, from $11.0 million in the prior quarter.
• Across five years, Receivables topped out at $16.5 million in Q1 2026 and bottomed at $132000.0 in Q2 2023.
• Historically, Receivables has averaged $7.7 million across 5 years, with a median of $7.1 million in 2022.
• Annual changes were most pronounced in 2023 — Receivables tumbled 97.61% — and 2024, when it soared 6751.52%.
• Niagen Bioscience's Receivables stood at $6.9 million in 2022, then slipped by 28.91% to $4.9 million in 2023, then surged by 45.85% to $7.1 million in 2024, then jumped by 54.41% to $11.0 million in 2025, then jumped by 50.07% to $16.5 million in 2026.
• Business Quant data shows NAGE's Receivables at $16.5 million in Q1 2026, $11.0 million in Q4 2025, and $7.3 million in Q3 2025.